Facial reconstruction

Search LJMU Research Online

Browse Repository | Browse E-Theses

Potential Cardio-Protective Agents: A Resveratrol Review (2000-2019)

Houacine, C, Khan, I and Yousaf, SS (2020) Potential Cardio-Protective Agents: A Resveratrol Review (2000-2019). Current Pharmaceutical Design, 27 (26). pp. 2943-2955. ISSN 1381-6128

Potential cardio-protective agents A Resveratrol review (2000-2019).pdf - Accepted Version

Download (699kB) | Preview


With a 2030 projection of 23.6 million deaths per year, the prevalence and severity of cardiovascular disease are astoundingly high. Thus, there is a definitive need for the identification of novel compounds with the potential to prevent or treat the disease and associated states. Moreover, there is also an ever-increasing need for drug delivery systems (DDS) that cope with poor and ranging physiochemical properties of therapeutic compounds to achieve the clinical effect. The usage of resveratrol (RES) is a growing area of interest with innu-merate pieces of research, evidencing the drug’s efficacy. This drug is, however, marred; its notably poor phy-siochemical properties (namely poor water solubility) limit its use for oral drug delivery. RES analogues, how-ever, potentially possess superior physiochemical characteristics offering a remedy for the aforementioned drawback. However, particulate based DDS are equally able to offer property amelioration and targeting. This review offers an extensive examination into the role of RES as a potential cardioprotective agent. The prevalence and suitability of associated analogues and the role of nanotechnology in overcoming physicochemical boundaries, particularly through the development of nanoparticulate formulations, will be discussed in detail.

Item Type: Article
Additional Information: The published manuscript is available at EurekaSelect via http://www.eurekaselect.com/10.2174/1381612826666200909125354
Uncontrolled Keywords: Science & Technology; Life Sciences & Biomedicine; Pharmacology & Pharmacy; Resveratrol; cardiovascular disease; bioavailability; nanotechnology; DDS; NANOSTRUCTURED LIPID CARRIERS; SPRAGUE-DAWLEY RATS; CARDIOVASCULAR-DISEASE; IN-VITRO; CARDIAC-HYPERTROPHY; DRUG-DELIVERY; ORAL DELIVERY; HEART-FAILURE; NITRIC-OXIDE; RED WINE; Humans; Cardiotonic Agents; Drug Delivery Systems; Biological Availability; Solubility; Resveratrol; DDS; Resveratrol; bioavailability; cardiovascular disease; nanotechnology; resveratrol.; Biological Availability; Cardiotonic Agents; Drug Delivery Systems; Humans; Resveratrol; Solubility; Medicinal & Biomolecular Chemistry; 1115 Pharmacology and Pharmaceutical Sciences
Subjects: R Medicine > RM Therapeutics. Pharmacology
Divisions: Pharmacy & Biomolecular Sciences
Publisher: Bentham Science Publishers
SWORD Depositor: A Symplectic
Date Deposited: 28 Jun 2022 10:50
Last Modified: 28 Jun 2022 11:00
DOI or ID number: 10.2174/1381612826666200909125354
URI: https://researchonline.ljmu.ac.uk/id/eprint/17170
View Item View Item